Loading
A phase 1/2 trial of TAK-505 in advanced solid tumours, run by Takeda, now recruiting.
A Study of TAK-505 in Adults With Solid Tumors is a phase 1/2 interventional study registered as NCT07436728 by Takeda, with 151 participants planned, started 2026-05-11 and due to reach its primary completion in 2030-08-18. Interventions recorded: TAK-505.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Takeda, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Takeda and the tag pipeline.
Shares Takeda and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/